BNP Paribas Financial Markets
NKGN

BNP Paribas Financial Markets’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

BNP Paribas Financial Markets’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-900,000
Closed -$7.33M – 4723
2022
Q3 		$7.33M Buy
+900,000
New +$8.78M 0.01% 1159

Other funds holding NKGN

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 13.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
CIM
Cowen Investment Management New York $12M AUM 1.47% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return

BNP Paribas Financial Markets's NKGN Position: Q4 2022 in Review

BNP Paribas Financial Markets sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q4 2022, closing a stake of 900,000 shares — an estimated $7.33M sold.

BNP Paribas Financial Markets first reported a position in NKGN in Q3 2022 and held it in 1 quarter. The position peaked at $7.33M in Q3 2022. 59 funds tracked by Wall St. Rank hold NKGN as of Q4 2022.

  • BNP Paribas Financial Markets reported no remaining NKGen Biotech, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 900,000 NKGen Biotech, Inc. Common Stock shares in Q4 2022, an estimated $7.33M.
  • BNP Paribas Financial Markets first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • BNP Paribas Financial Markets's NKGen Biotech, Inc. Common Stock position peaked at $7.33M in Q3 2022.
  • 59 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q4 2022.

Based on BNP Paribas Financial Markets's 13F filing for Q4 2022, filed 14 Feb 2023.